BIIB Price Prediction Next Week
BIIB Stock Price Prediction and Recommendation
Technical Analysis:
- Current Price: $141.79 (as of 2025-03-24).
- RSI: 41.53 (RSI_6), indicating a neutral position.
- Moving Averages: Below the 200-day SMA ($180.17), but near shorter-term SMAs (SMA_5: $142.07, SMA_10: $142.43).
- MACD: Slightly negative (-0.32), suggesting bearish momentum.
- Fibonacci Levels: Pivot at $146.05, resistance at $153.10 and $157.46, support at $139 and $134.64.
News and Fundamental Analysis:
- Earnings: Q4 showed a 3% revenue increase and 17% EPS growth, but BIIB expects a revenue decline in 2025.
- Analyst Sentiment: "Moderate Buy" rating with a mean target of $197.55, indicating potential upside.
- Sector Challenges: High levies in the UK may affect investment and growth in the pharmaceutical sector.
Prediction and Recommendation:
- Price Target: $153.10 (Fibonacci resistance level).
- Recommendation: Sell if the stock approaches resistance without breaking through, considering the bearish technical indicators and sector challenges.
BIIB Similar Chart Price Prediction
The price of BIIB is predicted to go up 20.54%, based on the high correlation periods with MTCH. The similarity of these two price pattern on the periods is 93.06%.
BIIB
MTCH
Up: 20.54%Similarity: 93.06%
BIIB Revenue Forecast
BIIB EPS Forecast
BIIB FAQs
What is BIIB revenue forecast for next quarter？
What is BIIB eps forecast for next quarter？
BIIB VS S&P500
Biogen leads the $20 billion global MS market with Avonex, Plegridy, Tysabri, and Tecfidera. The launch of Vumerity partly protects Tecfidera sales from generic headwinds in the U.S.
Biogen receives royalties and profit share from Roche on MS drug Ocrevus and multiple CD20-targeted cancer therapies, boosting profitability.
Biogen's neurology portfolio outside of MS, including Leqembi in Alzheimer's, should help diversify revenue and boost sales growth.
BIIB Analyst's Forecast
Salveen Richter
Goldman Sachs
Strong Buy
2025-02-13
Price Target
$281 → $245
Upside
+77.32%
Goldman Sachs lowered the firm's price target on Biogen to $245 from $281 but keeps a Buy rating on the shares. The firm cites the company's FY25 guidance indicating a mid-single digit y/y revenue decline and lower than expected EPS on FX headwinds, the analyst tells investors in a research note. The firm adds that it expects Biogen shares to remain range bound amid execution on BD/M&A, where the management is interested in rare disease/immunology/potentially neurology and smaller/earlier-stage deals as well as the recognition of late-stage pipeline value.
Geoff Meacham
Citigroup
Hold
2025-02-13
Price Target
$160 → $145
Upside
+4.94%
Mohit Bansal
Wells Fargo
Hold
2025-02-13
Price Target
$165 → $140
Upside
+1.32%
